
Indirect Comparison Analysis of Head-to-Head Migraine Trials Suggests Early Efficacy Advantage With Atogepant Over Erenumab
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxQdEM0UTlLbmdSYnBfWWg4LUdRRWpDdVpLRkVOYUNBbEYwSjBvZ0VzUGdyTEpWcmd1RXJ1STlHY2MtMjNGSnNZNFRSWmRmbXJqSERnSExlTmctMnphVEhzUTZVNExPMEt2RXNkT0EtNDFoWUZSR2p6MENySGZPRXNaMDBIazROU1NNYk1RREFoM01YRlZaei1sWnJ2WHc2SmlZMXNBcDhJQWJ4MW1kU3hkYWRNaTVtSVRRUnptV3RLSXdiYzcyRFk5Z3dGSHBTYXQ5OUptWU8ySV93XzV1RkRTQW80VEQ?oc=5" target="_blank">Indirect Comparison Analysis of Head-to-Head Migraine Trials Suggests Early Efficacy Advantage With Atogepant Over Erenumab</a>&nbsp;&nbsp;<font color="#6f6f6f">NeurologyLive</font>
